US-based Strathspey Crown Holdings’ subsidiary Alphaeon has signed a co-promotion agreement with Tracey Technologies to market next-generation iTrace platform.

The company developed iTrace to measure patients’ quality of vision with patented forward ray tracing technology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Alphaeon will be a co-exclusive sales representative with Tracey, offering the iTrace next-generation platform to ophthalmologists, within the US.

Ophthalmologists can identify internal aberrations using iTrace, and it also helps them to determine the best refractive procedure and customise lens implant for each patient.

"The company developed iTrace to measure patients’ quality of vision with patented forward ray tracing technology."

Alphaeon CEO Robert Grant said: "iTrace is a great complement to our developing ophthalmic technology offering, integrating with TouchMD to further enhance the patient education experience.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Medical Device Network.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to initiate selling the next-generation iTrace platform from this month.

Tracey Technologies CEO Joe Wakil said: "We believe diagnostic information available in the iTrace, like the new dysfunctional lens analysis, will provide Alphaeon’s customers with quality of vision tools that will improve patient care and ultimately practice performance."

Tracey develops and manufactures advanced refractive diagnostic devices ,and produces devices integrating ray tracing aberrometry wavefront analysis with advanced corneal topography analysis. The iTrace series of products has been offered since 2008.

Image: Alphaeon Corporation Headquarters, Irvine, California. Photo: courtesy of PRNewswire / ALPHAEON Corporation.